US20130302855 refers to a patent application related to acarbose. Acarbose is a medication used to manage type 2 diabetes by slowing down the digestion of carbohydrates [1].
What is US20130302855 about?
This patent application, published in 2013, describes methods for preparing acarbose [1]. The details within the application likely pertain to specific manufacturing processes, purifications, or formulations of the drug [1].
How does acarbose work for diabetes?
Acarbose functions as an alpha-glucosidase inhibitor. It works in the small intestine by delaying the breakdown of complex carbohydrates into simpler sugars, thereby reducing the post-meal spike in blood glucose levels [1]. This mechanism helps improve glycemic control in individuals with type 2 diabetes [1].
When does acarbose patent exclusivity expire?
Patent exclusivity for specific acarbose formulations or manufacturing processes would have depended on the filing and issuance dates of various patents. For a broad understanding of acarbose patent timelines, resources like DrugPatentWatch.com can provide detailed information [2].
Can generic versions of acarbose be produced?
Once patents protecting acarbose expire, generic manufacturers can seek approval to produce and market their versions of the drug. The availability of generic acarbose depends on the expiration of relevant patents and regulatory approvals in different regions [2].
What are the side effects of acarbose?
Common side effects associated with acarbose include gastrointestinal issues such as diarrhea, abdominal pain, and flatulence [1]. These effects are often related to the undigested carbohydrates reaching the large intestine [1].
How does acarbose compare to other diabetes medications?
Acarbose belongs to a class of drugs distinct from others like metformin or sulfonylureas. While metformin primarily reduces glucose production by the liver and increases insulin sensitivity, and sulfonylureas stimulate insulin release, acarbose targets carbohydrate digestion [3]. Its use is often as an adjunct therapy to diet and exercise, or in combination with other oral antidiabetic agents [3].
Sources:
[1] US20130302855
[2] https://drugpatentwatch.com/
[3] Information on diabetes medications